Sino Biopharmaceutical (SMZ1) Stock Statistics & Valuation Metrics

Sino Biopharmaceutical has a market cap or net worth of CHF8.86B. The enterprise value is CHF115.61K.

Sino Biopharmaceutical has 18,682,953,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sino Biopharmaceutical’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 8.98%.

The current PE Ratio of Sino Biopharmaceutical is 31.7. Sino Biopharmaceutical’s PEG ratio is -1.22.

In the last 12 months, Sino Biopharmaceutical had revenue of 31.83B and earned 2.34B in profits. Earnings per share was 0.13.

In the last 12 months, operating cash flow was 9.29B and capital expenditures -1.24B, giving a free cash flow of 8.05B billion.

Sino Biopharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―

Sino Biopharmaceutical upcoming earnings date is Apr 1, 2027, TBA (Confirmed).

Sino Biopharmaceutical as a current ratio of 1.37, with Debt / Equity ratio of 52.39%

In the past 12 months, Sino Biopharmaceutical has paid 1.63B in taxes.

Sino Biopharmaceutical EV to EBITDA ratio is 15.01, with an EV/FCF ratio of 14.35.

Sino Biopharmaceutical has CHF22.56B in cash and marketable securities with CHF16.07B in debt, giving a net cash position of CHF6.49B billion.

Gross margin is 82.07%, with operating margin of 21.84%, and net profit margin of 7.36%.

The average price target for Sino Biopharmaceutical is CHF0.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy